Vinblastine

Vinblastine is a vinca alkaloid derived from Catharanthus roseus (periwinkle plant) that functions as a mitotic inhibitor by binding to tubulin dimers. It prevents microtubule polymerization, arresting cell division at metaphase and triggering apoptosis in rapidly dividing cancer cells.

Origin & History

Vinblastine is a vinca alkaloid naturally derived from the Madagascar periwinkle plant (Catharanthus roseus), extracted from the plant's leaves. It belongs to the class of dimeric indole alkaloids and functions as a mitotic inhibitor in cancer chemotherapy by binding to tubulin and disrupting microtubule formation.

Historical & Cultural Context

Vinblastine is not a traditional medicine compound but rather a modern pharmaceutical alkaloid isolated from the Madagascar periwinkle in the 20th century. While the periwinkle plant has been used in traditional medicine systems, vinblastine itself represents a transition from ethnobotanical observation to modern oncology development.

Health Benefits

• Treatment of Hodgkin lymphoma with 72.7% complete remission rate in phase 2 trial (CALGB 50203) with 99 patients • Management of high-risk anaplastic large-cell lymphoma in pediatric populations, as demonstrated in the ALCL99-vinblastine trial with 217 patients • Treatment option for urothelial cancer in cisplatin-ineligible patients, though with modest survival benefit (median 8.1 months) in phase II/III trial • Therapeutic activity in doxorubicin-refractory metastatic breast cancer when administered as continuous infusion • Component of neoadjuvant therapy for muscle-invasive bladder cancer in the BA06 30894 international phase III trial with 976 patients

How It Works

Vinblastine binds with high affinity to beta-tubulin at the vinca domain, preventing tubulin heterodimer polymerization into functional mitotic spindles and inducing tubulin spiral aggregation. This disruption arrests the cell cycle at the G2/M phase metaphase checkpoint, activating the spindle assembly checkpoint via Mad2 and BubR1 kinase signaling. Prolonged mitotic arrest triggers caspase-dependent apoptosis, particularly affecting rapidly proliferating cells with high mitotic indices such as lymphoma and carcinoma cells.

Scientific Research

Multiple randomized controlled trials have evaluated vinblastine across various cancers, including the CALGB 50203 trial in Hodgkin lymphoma (99 patients), the ALCL99-vinblastine trial in pediatric lymphoma (217 patients), and a phase II/III trial in urothelial cancer (238 patients). The BA06 30894 international phase III trial assessed neoadjuvant CMV chemotherapy in 976 patients with muscle-invasive bladder cancer over 8 years of follow-up.

Clinical Summary

A Phase 2 CALGB 50203 trial in 99 patients with Hodgkin lymphoma demonstrated a 72.7% complete remission rate when vinblastine was incorporated into ABVD-based regimens, providing strong prospective evidence for its role in first-line therapy. The ALCL99-vinblastine randomized trial in 217 pediatric patients with high-risk anaplastic large-cell lymphoma showed that vinblastine maintenance improved event-free survival compared to standard chemotherapy alone. Vinblastine also serves as a treatment option for urothelial carcinoma, typically in platinum-ineligible or relapsed settings, though evidence here derives largely from smaller cohort studies and retrospective analyses. Overall, the strongest evidence base exists for lymphoma indications, while its role in solid tumors requires further large-scale randomized validation.

Nutritional Profile

Vinblastine is a purified alkaloid compound derived from Catharanthus roseus (Madagascar periwinkle), not a nutritional substance. It has no macronutrient, micronutrient, fiber, or caloric value. Chemically, it is a dimeric indole-dihydroindole alkaloid with molecular formula C46H58N4O9 and molecular weight of 810.98 g/mol. It is composed primarily of two alkaloid units: vindoline and catharanthine linked via a carbon-carbon bond. Clinical formulations (Velban) are typically supplied as lyophilized powder at 10 mg per vial with mannitol as excipient. Bioavailability via oral route is negligible due to extensive first-pass metabolism and poor GI absorption; it is administered exclusively via intravenous injection. Plasma protein binding is approximately 75%. It undergoes hepatic metabolism via CYP3A4 to its active metabolite desacetylvinblastine. Half-life is triphasic: initial 3.7 minutes, intermediate 1.6 hours, terminal 24.8 hours. No dietary vitamins, minerals, or fiber content are applicable. As a vinca alkaloid, its bioactive mechanism involves tubulin binding (Kd approximately 1-2 µM), inhibiting microtubule polymerization rather than providing nutritional function.

Preparation & Dosage

Clinically studied dosages include 6 mg/m² per chemotherapy course for high-risk ALCL, 1.7 mg/m²/day by continuous infusion for metastatic breast cancer, and varying doses when combined with other agents in AVG and M-CAVI regimens. Vinblastine is administered intravenously as a pharmaceutical preparation with dosing calculated based on body surface area. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Doxorubicin, gemcitabine, methotrexate, carboplatin, cisplatin

Safety & Interactions

Vinblastine carries significant neurotoxicity risk, including peripheral neuropathy, paresthesia, and autonomic dysfunction such as constipation, ileus, and urinary retention due to axonal tubulin disruption. Severe myelosuppression—particularly leukopenia with nadir around days 5–10—is dose-limiting, requiring CBC monitoring and dose adjustments in hepatic impairment since the drug is primarily CYP3A4-metabolized and biliary-excreted. Concurrent use of strong CYP3A4 inhibitors (e.g., itraconazole, erythromycin) can markedly elevate plasma vinblastine levels, increasing toxicity risk, while P-glycoprotein inducers such as rifampin may reduce efficacy. Vinblastine is classified FDA Category D in pregnancy, with documented teratogenicity and fetotoxicity in animal models, and is contraindicated in breastfeeding.